valu usd unless otherwis note
result line guidanc
view revenu guidanc impli high-single-digit cc
growth midpoint adequ captur competit dynam
tavr market result next catalyst given binari
outcom ew share may remain range-bound next six week
rais price target reflect improv risk profil
futur cash flow follow resolut patent litig
ww revenu ep within guidanc ww revenu
y/i cc guidanc rel sale
estim product categori thv includ tmtt in-lin
shv cortic ahead tavr sale increas mid-
teen quarter european tavr sale increas low-
doubl digit market growth japan grew
estim non-gaap ep within guidanc line
consensu estim gross margin improv bp y/i fx
product mix oper margin bp growth expens
exceed sale growth free cash flow
revenu guidanc consist prior commentari steadi
ramp year consensu revenu ep
guidanc set
estim revenu guidanc assum ww tavr sale
q/q recent tavr survey intervent
cardiologist predict low/mid-single-digit sequenti growth
 ew recent commenc control launch two
new aortic replac valvessapien ultra europ
centera europeallow tavr center time becom familiar
differ valv sapien revenu
contribut new valv meaning
new product sustain revenu trend surgic heart
valv critic shv sale increas cc
respect correspond figur critic
shv intuiti elit inspiri
resilia continu perform well help maintain sale growth
surgic aortic valv despit on-going shift toward tavr inspiri
resilia becam commerci avail japan
launch hemospher ew next-gener all-in-on hemodynam
monitor platform main growth driver critic
compani announc two new gpo contract
chang guidanc ew re-affirmed guidanc ww
revenu tavr tmtt non-gaap
ep ew expect ce mark pascal mitral repair valv
therefor sale ramp pascal key variabl
meet tmtt forecast base find tavr survey
believ ew tavr forecast achiev upward revis
appear unlik
price prior trade day market close estimate unless otherwis note
ew remain attract multi-year growth stori large-
cap med-tech view believ ew deliv
revenu compound-annual-growth-rate next three year
growth rate large-cap compani coverag
manag project ww tavr market
growth driver includ continu
penetr intermediate-risk sever symptomat aortic
stenosi patient expans low-risk popul
onward potenti approv asymptomat
patient basi early-tavr trial improv
patient awar tavr time
manag set realist revenu forecast
ew project total revenu growth
compani expect report
despit competit price reimburs
pressur demonstr underli strength ew
tavr franchis ew also expect sale contribut
transcathet mitral tricuspid therapi tmtt
tmtt pipelin advanc pascal two separ
trial end primari secondari
deliv transsept also enter trial
trial cardioband tricuspid regurgit start
late well
ew forecast tmtt market believ
variou therapi option compani develop
yield least market share impli
annual sale given size market opportun
inher complex treat mitral valv diseas
room multipl compani flourish view
bloomberg capit market estim upside/downside/target
dcf model yield base case price target key
assumpt follow revenu compound-annual-growth-rate
driven double-digit growth tavr/
mitral franchis mid-single-digit growth two
product categori surgic valv critic ebit
margin tax rate
forecast period cash flow dcf
model discount use wacc
upsid scenario valu assum low-double-digit
revenu growth compound-annual-growth-rate driven
expans moder aortic stenosi asymptomat
along meaning revenu contribut
downsid scenario valu assum moder
tavr revenu growth due slower adopt among
intermediate-risk patient delay approv low-risk
indic stronger competit lack
progress mitral clinic develop program
exhibit estim guidanc
note guidanc y/i revenu growth rate signifi tighter rang compar growth rate impli guidanc rang dollar
exhibit ww tavr sale sale growth roll four quarter
exhibit ww surgic heart valv sale sale growth roll four quarter
exhibit ww critic sale sale growth roll four quarter
exhibit estim vs report result
dcf model yield base case price target key assumpt follow
revenu growth compound-annual-growth-rate driven double-digit growth tavr/
mitral franchis mid-single-digit growth two product categori surgic
valv critic ebit margin tax rate
forecast period cash flow dcf model discount use wacc
price target support outperform rate
risk rate price target
risk price target rate includ limit increas competit
market opportun currenc litig reimburs clinic trial risk
edward lifesci global player product technolog design treat
cardiovascular diseas compani focus specif cardiovascular opportun
includ heart valv diseas critic care technolog peripher vascular diseas
